Vascular and cardiac functional and structural screening to identify risk of future morbid events: Preliminary observations

Daniel Duprez, Natalia Florea, Wei Zhong, Gregory A Grandits, Caitlin K. Hawthorne, Lynn Hoke, Jay N Cohn

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Risk factors have served to identify patients in need of antihypertensive and lipid-lowering therapy. Because of their limited sensitivity and specificity, we developed a screening program using noninvasive testing and a scoring system aimed at detecting functional and structural cardiovascular abnormalities in asymptomatic individuals. Ten cardiovascular tests were performed in 1 hour by a single technologist. Tests were scored as normal (0), borderline abnormal (1), or abnormal (2). Total disease score (DS) could range from 0 (all tests normal) to 20 (all tests abnormal). Scores of 0-2 were classified as normal, 3-5 as early disease, and 6+ as advanced disease. Morbid events during follow-up of 6 months to 8 years were determined from mailed questionnaires. Framingham risk scores (FRS) were calculated using published algorithms. Thirty-five morbid events (1 of 169 in the "normal" group, 8 of 214 in the "early disease" group, and 26 of 230 in the "advanced disease" group) occurred during the follow-up period among the 613 individuals who completed the questionnaire. Risk for morbid events was highly significantly different between the Kaplan-Meier curves based on disease detection (log rank 21.75, P ≤.0001). FRS were significantly different but less discriminating, with five morbid events in the 227 subjects with FRS <10, eight in 162 with FRS 10-13, and 22 of 227 with FRS >13 (log rank 9.80, P =.0074). The area under receiver operating characteristic curve for DS (0.74) surpassed that of FRS (0.66) and was not improved when both were included in the model. Neither blood pressure levels nor low-density lipoprotein cholesterol levels provided adequate discrimination. Identifying early disease in asymptomatic individuals provides a better guide to the need for preventive therapy than traditional risk factor assessment.

Original languageEnglish (US)
Pages (from-to)401-409
Number of pages9
JournalJournal of the American Society of Hypertension
Issue number5
StatePublished - Sep 2011

Bibliographical note

Funding Information:
Conflict of interest: Jay N. Cohn, MD, has equity positions in Hypertension Diagnostics, Inc., the manufacturer of the CV Profilor used in the Center, and in Cohn Prevention Centers, LLC, whose goal is to establish prevention centers elsewhere. He is the Principal Investigator on research grants funded by GlaxoSmithKline and Forest Laboratories .


  • Atherosclerosis
  • blood pressure
  • cholesterol
  • early detection


Dive into the research topics of 'Vascular and cardiac functional and structural screening to identify risk of future morbid events: Preliminary observations'. Together they form a unique fingerprint.

Cite this